Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All budesonide studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBudesonideBudesonide (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Association Between Inhaled Corticosteroid Use and the Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Nationwide Population-based Study in South Korea

Lee et al., Research Square, doi:10.21203/rs.3.rs-72221/v1
Sep 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Case 33% Improvement Relative Risk Budesonide for COVID-19  Lee et al.  Prophylaxis Does budesonide reduce COVID-19 infections? Retrospective 7,019 patients in South Korea Fewer cases with budesonide (not stat. sig., p=0.098) c19early.org Lee et al., Research Square, September 2021 Favorsbudesonide Favorscontrol 0 0.5 1 1.5 2+
Budesonide for COVID-19
19th treatment shown to reduce risk in April 2021
 
*, now with p = 0.0000011 from 15 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Retrospective 44,968 patients in South Korea, 7,019 on inhaled corticosteroids, showing no statistically significant differences in COVID-19 cases.
Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects.
risk of case, 32.6% lower, RR 0.67, p = 0.10, treatment 19 of 1,674 (1.1%), control 95 of 5,345 (1.8%), NNT 156, adjusted per study, odds ratio converted to relative risk, multivariate.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lee et al., 9 Sep 2021, retrospective, South Korea, preprint, 5 authors.
This PaperBudesonideAll
Association Between Inhaled Corticosteroid Use and the Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Nationwide Population-based Study in South Korea
Sang Chul Lee, Kang Ju Son, Chang Hoon Han, Ji Ye Jung, Seon Cheol Park
doi:10.21203/rs.3.rs-72221/v1
Background Inhaled corticosteroid (ICS) use may increase the risk of respiratory infection, but its in uence on the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not known. This study aimed to investigate the association between ICS use and the risk of SARS-CoV-2 infection among the patients with chronic respiratory diseases. Methods The Ministry of Health and Welfare and Health Insurance Review and Assessment Service in Korea provided nationwide data of 44,968 individuals with chronic respiratory diseases tested for SARS-CoV-2 until May 15. The risks of SARS-CoV-2 infection were retrospectively analysed according to the prescription, type, and dose of ICS taken one year before SARS-CoV-2 test. Results Among 44,968 individuals tested, 931 (2.1%) were positive for SARS-CoV-2. A total of 7,019 patients (15.6%) were prescribed ICS one year prior to being tested for SARS-CoV-2. Low, medium, and high doses of ICS were prescribed in 7.5%, 1.6%, and 6.5% of total cases, respectively. Among the types of ICS, budesonide, uticasone, beclomethasone, and ciclesonide were prescribed in 3.7%, 8.9%, 2.3%, and 0.6% of total cases, respectively. The multivariate analysis showed no signi cant increase in infection with ICS use (OR, 0.84; 95% CI, 0.66-1.03). Moreover, there were no associations between the risk of infection, and doses or types of ICS prescribed. Conclusion Prior ICS use did not increase the risk of SARS-CoV-2 infection. Moreover, different doses or types of ICS did not affect the risk. This study supports the current guidelines to manage patients taking ICS during the SARS-CoV-2 pandemic.
Declarations Ethics approval and consent to participate: This study was approved by the Institutional Review Board of the National Health Insurance Service of the Ilsan Hospital and adhered to the tenets of the Declaration of Helsinki (NHIMC 2020-04-008). Written informed consent was waived as the data were de-identi ed in the database used. Consent for publication: Not Con icts of interest: The authors declare that they have no relevant con icts of interest. Author's contributions: Supplementary Files This is a list of supplementary les associated with this preprint. Click to download. COVID19andICSRespiratoryResearchSuppl.docx
References
Andréjak, Nielsen, Thomsen, Duhaut, Sørensen et al., Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis, Thorax
Brode, Campitelli, Kwong, Lu, Marchand-Austin et al., The risk of mycobacterial infections associated with inhaled corticosteroid use, Eur Respir J
Charlson, Pompei, Ales, Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Gif, Global strategy for asthma management and prevention
Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Halpin, Faner, Sibila, Badia, Agusti, Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?, Lancet Respir Med
Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell
Iwabuchi, Kurakami, Takahashi, Kato, Morishima, Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases, J Infect Chemother
Janson, Stratelis, Miller-Larsson, Harrison, Larsson, Scienti c rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD, Int J Chron Obstruct Pulmon Dis
Kew, Seniukovich, Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease, Cochrane Database Syst Rev, doi:10.1002/14651858.CD010115.pub2
Kim, Rhee, Shim, Park, Yoo et al., Inhaled Corticosteroids in Asthma and the Risk of Pneumonia, Allergy Asthma Immunol Res
Lee, Kim, Hyun, Jang, Lee et al., Use of inhaled corticosteroids and the risk of tuberculosis, Thorax
Matsuyama, Kawase, Nao, Shirato, Ujike et al., The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15, bioRxiv, doi:10.1101/2020.03.11.987016.2020
Mckeever, Harrison, Hubbard, Shaw, Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study, Chest
O'byrne, Pedersen, Carlsson, Radner, Thorén et al., Risks of pneumonia in patients with asthma taking inhaled corticosteroids, Am J Respir Crit Care Med
Organization, Coronavirus disease (COVID-2019) situation reports
Peters, Sajuthi, Deford, Christenson, Rios et al., COVID-19 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids, Am J Respir Crit Care Med, doi:10.1164/rccm.202003-0821OC
Singanayagam, Glanville, Girkin, Ching, Marcellini et al., Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations, Nat Commun
Suissa, Mcghan, Niewoehner, Make, Inhaled corticosteroids in chronic obstructive pulmonary disease, Proc Am Thorac Soc
Yamaya, Nishimura, Deng, Sugawara, Watanabe et al., Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells, Respir Investig
Yan, Zhang, Li, Xia, Guo et al., Structural basis for the recognition of SARS-CoV-2 by fulllength human ACE2, Science
Yang, Chen, Zhang, Du, Xu et al., Long-term of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis, Inhal Toxicol
Yang, Zhang, Chen, Lin, Zeng et al., Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis, Infection
Yang, Zheng, Gou, Pu, Chen et al., Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis, Int J Infect Dis
Zhu, Zhang, Li, Yang, Song, GINA-GLOBAL Initiative for Asthma HIRA-Health Insurance Review and Assessment Service ICS-Inhaled corticosteroid OR-Odds ratio SARS-CoV-2-Severe acute respiratory syndrome coronavirus 2 TMPRSS2-Transmembrane protease serine 2 URTI-Upper respiratory tract infection References, N Engl J Med
{ 'institution': [{'name': 'Research Square'}], 'indexed': {'date-parts': [[2022, 4, 4]], 'date-time': '2022-04-04T12:53:35Z', 'timestamp': 1649076815932}, 'posted': {'date-parts': [[2020, 9, 9]]}, 'group-title': 'In Review', 'reference-count': 0, 'publisher': 'Research Square Platform LLC', 'license': [ { 'start': { 'date-parts': [[2020, 9, 9]], 'date-time': '2020-09-09T00:00:00Z', 'timestamp': 1599609600000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 9, 4]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>Background\n' '\n' 'Inhaled corticosteroid (ICS) use may increase the risk of respiratory infection, but its ' 'influence on the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ' 'infection is not known. This study aimed to investigate the association between ICS use and ' 'the risk of SARS-CoV-2 infection among the patients with chronic respiratory diseases.\n' 'Methods\n' '\n' 'The Ministry of Health and Welfare and Health Insurance Review and Assessment Service in ' 'Korea provided nationwide data of 44,968 individuals with chronic respiratory diseases tested ' 'for SARS-CoV-2 until May 15. The risks of SARS-CoV-2 infection were retrospectively analysed ' 'according to the prescription, type, and dose of ICS taken one year before SARS-CoV-2 test.\n' 'Results\n' '\n' 'Among 44,968 individuals tested, 931 (2.1%) were positive for SARS-CoV-2. A total of 7,019 ' 'patients (15.6%) were prescribed ICS one year prior to being tested for SARS-CoV-2. Low, ' 'medium, and high doses of ICS were prescribed in 7.5%, 1.6%, and 6.5% of total cases, ' 'respectively. Among the types of ICS, budesonide, fluticasone, beclomethasone, and ' 'ciclesonide were prescribed in 3.7%, 8.9%, 2.3%, and 0.6% of total cases, respectively. The ' 'multivariate analysis showed no significant increase in infection with ICS use (OR, 0.84; 95% ' 'CI, 0.66–1.03). Moreover, there were no associations between the risk of infection, and doses ' 'or types of ICS prescribed.\n' 'Conclusion\n' '\n' 'Prior ICS use did not increase the risk of SARS-CoV-2 infection. Moreover, different doses or ' 'types of ICS did not affect the risk. This study supports the current guidelines to manage ' 'patients taking ICS during the SARS-CoV-2 pandemic.</jats:p>', 'DOI': '10.21203/rs.3.rs-72221/v1', 'type': 'posted-content', 'created': {'date-parts': [[2020, 9, 9]], 'date-time': '2020-09-09T16:55:28Z', 'timestamp': 1599670528000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Association Between Inhaled Corticosteroid Use and the Severe Acute Respiratory Syndrome ' 'Coronavirus 2 Infection: A Nationwide Population-based Study in South Korea', 'prefix': '10.21203', 'author': [ { 'given': 'Sang Chul', 'family': 'Lee', 'sequence': 'first', 'affiliation': [{'name': 'National Health Insurance Service Ilsan Hospital'}]}, { 'given': 'Kang Ju', 'family': 'Son', 'sequence': 'additional', 'affiliation': [{'name': 'National Health Insurance Service Ilsan Hospital'}]}, { 'given': 'Chang Hoon', 'family': 'Han', 'sequence': 'additional', 'affiliation': [{'name': 'National Health Insurance Service Ilsan Hospital'}]}, { 'ORCID': 'http://orcid.org/0000-0003-1589-4142', 'authenticated-orcid': False, 'given': 'Ji Ye', 'family': 'Jung', 'sequence': 'additional', 'affiliation': [{'name': 'Yonsei University College of Medicine'}]}, { 'given': 'Seon Cheol', 'family': 'Park', 'sequence': 'additional', 'affiliation': [{'name': 'National Health Insurance Service Ilsan Hospital'}]}], 'member': '8761', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://www.researchsquare.com/article/rs-72221/v1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.researchsquare.com/article/rs-72221/v1.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 3, 17]], 'date-time': '2021-03-17T18:45:48Z', 'timestamp': 1616006748000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.researchsquare.com/article/rs-72221/v1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 9, 9]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.21203/rs.3.rs-72221/v1', 'relation': {}, 'published': {'date-parts': [[2020, 9, 9]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit